management

Torbjørn Bjerke
CEO since 2011.
Born 1962. MD.
Torbjørn Bjerke has over 20 years of experience in the pharmaceutical industry including roles as President and CEO of Orexo AB a position he held from 2007 until January 2011, President and CEO of Biolipox AB and Director of Pharmacology at AstraZeneca. He has also served as manager of R&D at ALK-Abello.

Other appointments
Board member of NeuroSearch AS and Paris based DBV Technologies.

Holdings in Karolinska Development: 11 375 shares and 0 warrants.

Terje Kalland
CSO since 2011.
Born 1951. MD. PhD.
Terje Kalland has over 20 years experience from leading positions in the pharmaceutical industry, including roles as Senior Vice President, Biopharmaceuticals Research at Novo Nordisk 2005-2011, CSO of Biovitrum (2002-2005) and Global head of Oncology Research at Pharmacia Corporation (1988-2002). Terje Kalland is a member of The Royal Swedish Academy of Engineering Sciences. 

Other appointments
Member of the Board of Directors of CBIO Ltd.

Holdings in Karolinska Development: 0 shares and 0 warrants.

Gunnar Casserstedt
CFO since 2006 and deputy CEO since 2007.
Born 1950. M.Sc. in Business Economics.
Gunnar Casserstedt has over 30 years experience in senior positions in the pharmaceutical and biotechnology industry, including Vice President R&D Finance at Pharmacia Inc., as well as CFO of Sopherion Therapeutics Inc.

Other appointments
Chairman of KCIF Fund Management AB.

Holdings in Karolinska Development: 11 799 shares and 31 220 warrants.

Benjamin Nordin
IRO since 2011.
Born 1974. M.Sc. molecular biology.

Benjamin Nordin has over 10 years experience as an analyst within the life science sector, including as Sector Head, Health Care, Equity Research at Kaupthing Bank, and positions at Karolinska Institutet Centre for Medical Innovations and JP Nordiska. 

Holdings in Karolinska Development: 200 shares and 0 warrants.

Robin Wright 
Head of Business Development since 2011.
Born 1964.  BA (Oxon), ACA.

Robin Wright has over 20 years experience in corporate financial management, investment banking and deal-making in the pharmaceutical industry, including positions as CFO of Orexo AB and Pan-European Food Fund, Head of Pharmaceutical M&A at Citibank and Head of Corporate Finance at Bioscience Managers. Robin will become Chief Financial Officer in May 2012.

Other appointments
Chariman of Dilaforette Holdings AB and Dilaforette AB. Board memeber of Dilafor AB and KDev Oncology AB.

Holdings in Karolinska Development: 0 and 0 warrants.

Otto Skolling
Vice President Business Development since 2012.
(VP Portfolio Management 2007 - 2011).
Born 1961. M.Sc. Chemical Engineering.

Otto Skolling has 20 years experience in the pharmaceutical industry and medical technology, including within Novozymes, Siemens Life Support Systems and Pharmacia&Upjohn.

Other appointments
Board member of Athera Biotechnologies AB, BioChromix Pharma AB, Venture Cup Öst, Inhalation Sciences Sweden AB, NeoDynamics AB and XSpray Microparticles AB and alternate Board member of the Stockholm Uppsala Life Science AB.

Holdings in Karolinska Development: 5 591 shares and 62 219 warrants.

Ulf Richenberg 
General Counsel since 2008.
Born 1955. Master of Laws.
Ulf Richenberg has 25 years experience in business law, including positions as legal counsel of KIHAB, Esselte AB and Vattenfall; General Counsel of AB Stokab and Scribona AB and business law consultant of FOI.

Other appointments
Board memeber of KCIF Fund Management AB.

Holdings in Karolinska Development: 1 714 shares personally and 310 shares through related parties and 0 warrants.

Michael Sundström
VP Discovery Research since 2011.
PhD Born 1963.

Background Michael Sundström has nearly 20 years international experience from pharmaceutical and biotechnology organizations. He has held senior positions at Pharmacia, Structural Genomics Consortium at Oxford University and Novo Nordisk Foundation Center for Protein Research, where he has been Managing Director since 2007.

Other appointments
CEO of Actar AB.

Holdings in Karolinska Development: 2 000 shares.